Equities researchers at Cantor Fitzgerald lowered their FY2025 EPS estimates for Soleno Therapeutics in a research note issued to investors on Thursday, March 27th. Cantor Fitzgerald analyst K. Kluska ...

We recently published a list of 10 Stocks Outperform Broader Market Last Week. In this article, we are going to take a look ...

Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech ...

Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) shares were up 3.9% during trading on Friday after Stifel Nicolaus ...

Soleno Therapeutics stock has surged over 1,500% since September 2023, driven by the progress and today's FDA approval of ...

Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Soleno Therapeutics (SLNO) to $81 from $70 and keeps a Buy rating on ...

Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as ...

We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. In this article, we are going to take a ...

Soleno Therapeutics jumped on Thursday after the drugmaker won US approval for its drug to treat insatiable hunger caused by ...

PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...